Cargando…

Serum Exosomal EphA2 is a Prognostic Biomarker in Patients with Pancreatic Cancer

BACKGROUND: Pancreatic cancer (PC) is one of the worst prognoses amongst all malignant diseases. It is therefore of great significance to identify biomarkers with predictive clinical value for the prognosis and recurrence of PC. METHODS: In our study, enzyme-linked immunosorbent assays (ELISA) were...

Descripción completa

Detalles Bibliográficos
Autores principales: Wei, Qian, Li, Ze, Feng, Honglei, Ren, Li
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8112875/
https://www.ncbi.nlm.nih.gov/pubmed/33994808
http://dx.doi.org/10.2147/CMAR.S304719
_version_ 1783690755669229568
author Wei, Qian
Li, Ze
Feng, Honglei
Ren, Li
author_facet Wei, Qian
Li, Ze
Feng, Honglei
Ren, Li
author_sort Wei, Qian
collection PubMed
description BACKGROUND: Pancreatic cancer (PC) is one of the worst prognoses amongst all malignant diseases. It is therefore of great significance to identify biomarkers with predictive clinical value for the prognosis and recurrence of PC. METHODS: In our study, enzyme-linked immunosorbent assays (ELISA) were used to detect the expression of Exo-EphA2 in the serum of PC patients and controls. Kaplan–Meier curve and Cox regression analyses were used to evaluate the prognostic value of Exo-EphA2 expression in patients with primary and recurrent PC. RESULTS: The level of serum Exo-EphA2 was significantly higher in the PC group when compared to that of the control group. High expression of Exo-EphA2 in PC was associated with shorter overall survival (OS) and proved to be a significant negative prognostic factor in the multivariate analysis (HR = 1.04, 95% CI: 1.00–1.09, P <0.001). Additionally, we found that the level of serum Exo-EphA2 in recurrent PC patients (first recurrence < 12 months) was positively correlated with the level of Exo-EphA2 at primary diagnosis. Multivariate analysis showed that a high expression of Exo-EphA2 in recurrent PC was associated with shorter recurrence-free survival (RFS) (HR = 1.41, 95% CI: 1.10–1.70, P < 0.001). CONCLUSION: High expression of serum Exo-EphA2 represents a novel biomarker for a poor prognosis in PC patients.
format Online
Article
Text
id pubmed-8112875
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-81128752021-05-13 Serum Exosomal EphA2 is a Prognostic Biomarker in Patients with Pancreatic Cancer Wei, Qian Li, Ze Feng, Honglei Ren, Li Cancer Manag Res Original Research BACKGROUND: Pancreatic cancer (PC) is one of the worst prognoses amongst all malignant diseases. It is therefore of great significance to identify biomarkers with predictive clinical value for the prognosis and recurrence of PC. METHODS: In our study, enzyme-linked immunosorbent assays (ELISA) were used to detect the expression of Exo-EphA2 in the serum of PC patients and controls. Kaplan–Meier curve and Cox regression analyses were used to evaluate the prognostic value of Exo-EphA2 expression in patients with primary and recurrent PC. RESULTS: The level of serum Exo-EphA2 was significantly higher in the PC group when compared to that of the control group. High expression of Exo-EphA2 in PC was associated with shorter overall survival (OS) and proved to be a significant negative prognostic factor in the multivariate analysis (HR = 1.04, 95% CI: 1.00–1.09, P <0.001). Additionally, we found that the level of serum Exo-EphA2 in recurrent PC patients (first recurrence < 12 months) was positively correlated with the level of Exo-EphA2 at primary diagnosis. Multivariate analysis showed that a high expression of Exo-EphA2 in recurrent PC was associated with shorter recurrence-free survival (RFS) (HR = 1.41, 95% CI: 1.10–1.70, P < 0.001). CONCLUSION: High expression of serum Exo-EphA2 represents a novel biomarker for a poor prognosis in PC patients. Dove 2021-05-07 /pmc/articles/PMC8112875/ /pubmed/33994808 http://dx.doi.org/10.2147/CMAR.S304719 Text en © 2021 Wei et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Wei, Qian
Li, Ze
Feng, Honglei
Ren, Li
Serum Exosomal EphA2 is a Prognostic Biomarker in Patients with Pancreatic Cancer
title Serum Exosomal EphA2 is a Prognostic Biomarker in Patients with Pancreatic Cancer
title_full Serum Exosomal EphA2 is a Prognostic Biomarker in Patients with Pancreatic Cancer
title_fullStr Serum Exosomal EphA2 is a Prognostic Biomarker in Patients with Pancreatic Cancer
title_full_unstemmed Serum Exosomal EphA2 is a Prognostic Biomarker in Patients with Pancreatic Cancer
title_short Serum Exosomal EphA2 is a Prognostic Biomarker in Patients with Pancreatic Cancer
title_sort serum exosomal epha2 is a prognostic biomarker in patients with pancreatic cancer
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8112875/
https://www.ncbi.nlm.nih.gov/pubmed/33994808
http://dx.doi.org/10.2147/CMAR.S304719
work_keys_str_mv AT weiqian serumexosomalepha2isaprognosticbiomarkerinpatientswithpancreaticcancer
AT lize serumexosomalepha2isaprognosticbiomarkerinpatientswithpancreaticcancer
AT fenghonglei serumexosomalepha2isaprognosticbiomarkerinpatientswithpancreaticcancer
AT renli serumexosomalepha2isaprognosticbiomarkerinpatientswithpancreaticcancer